Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 12, 2012, Pages 2610-2612

  Verhoef, T I ^a   Redekop, W K ^b   Hegazy, H ^a   De Boer, A ^a   Maitland van der Zee, A H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE MULTIPROTEIN COMPLEX 1;

ALLELE; ANTICOAGULANT THERAPY; CONTROLLED STUDY; CYP2C9 GENE; DRUG EFFECT; DRUG INDICATION; GENE; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; VKORC1 GENE; WILD TYPE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHENPROCOUMON;

EID: 84871079113     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12007     Document Type: Letter

References (10)

1. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
2. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-92.
3. Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des 2010; 16: 187-203.
4. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, VAN DER Meer FJ, LE Cessie S, Wessels JA, Van Schie RM, DE Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; On behalf of the EU-PACT Group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012; 10: 606-14.
5. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32: 1909-17.
6. Schalekamp T, Brasse BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81: 185-93.
7. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90.
8. Federation of dutch anticoagulant clinics; samenvatting medische jaarverslagen, 2010. Available from: http://www.fnt.nl/media/docs/jaarverslagen/Jaarverslag_FNT_Medisch_2010.pdf [homepage on the Internet]. Accessed 15 August 2012.
9. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10: 1687-95.
10. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA; Ellenberg JH, Clarification of Optimal Anticoagulation through Genetics (COAG) Investigators. Statistical design of personalized medicine interventions: the clarification of optimal anticoagulation through genetics (COAG) trial. Trials 2010; 11: 108.